Anthony Palumbo and Charles Goulding analyze Boston Scientific’s US$14.5 billion acquisition of Penumbra, showing how additive manufacturing can accelerate thrombectomy and neurovascular innovation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results